Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on August 2, 2018, to report its financial results for the quarter ended June 30, 2018. The key information is contained within the furnished press release (Exhibit 99.1), which provides details on the company's operational and financial performance. Investors should note that this information is furnished, not filed, and thus may not be subject to the same liabilities under the Securities Exchange Act of 1934. The report itself is brief, serving primarily as a cover for the press release with the detailed financial and operational updates. The signature confirms that Manmeet S. Soni, Senior Vice President and Chief Financial Officer, authorized the filing.
Key Highlights
- 1Alnylam Pharmaceuticals reported its financial results for the quarter ended June 30, 2018.
- 2The detailed financial information is provided in a press release furnished as Exhibit 99.1.
- 3The filing is an 8-K, indicating a significant event or change for the company.
- 4The press release contains the core operational and financial performance data for the quarter.
- 5Information furnished under Item 2.02 is not considered 'filed' for Section 18 liability purposes.
- 6The filing was authorized by the Senior Vice President and Chief Financial Officer, Manmeet S. Soni.
Frequently Asked Questions
The detailed financial results and operational updates are provided in the press release furnished as Exhibit 99.1 to this Form 8-K filing, dated August 2, 2018.
Information furnished under Item 2.02 is typically for disclosure purposes but is not subject to the same liabilities under Section 18 of the Securities Exchange Act of 1934 as information that is 'filed'. This means the company may have less legal exposure for inaccuracies in furnished information compared to filed information.
The filing was signed by Manmeet S. Soni, Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals, Inc., on behalf of the company.